Literature DB >> 9138609

TGF-beta 1 mRNA expression in clinical breast cancer and its relationship to ER mRNA expression.

K D Amoils1, W R Bezwoda.   

Abstract

Eighty nine primary breast cancers were investigated for the expression of TGF-beta 1 and ER mRNA using PCR of reverse transcribed RNA. PCR products were validated using Southern blots and hybridization with radiolabelled cDNA probes. TGF beta 1 mRNA was found to be expressed in 56/89 (63%) of the breast cancers while ER mRNA was expressed in 23/89 (26%) of the tumours. Using chi-square analysis TGF-beta mRNA expression was found to correlate significantly with ER mRNA expression (p < 0.001), in that virtually all tumours that expressed ER mRNA co-expressed TGF beta 1. In tumours that were ER mRNA negative, TGF beta 1 expression was more variable. These results suggest that during tumour progression, ER expression is lost more frequently than is growth factor expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9138609     DOI: 10.1023/a:1005785421815

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Transforming growth factor-β1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung.

Authors:  Yoshihiro Minamiya; Masatomo Miura; Yudai Hinai; Hajime Saito; Manabu Ito; Takashi Ono; Hiroshi Toda; Satoru Motoyama; Jun-ichi Ogawa
Journal:  Tumour Biol       Date:  2010-05-27

2.  Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients.

Authors:  D Nikolić-Vukosavljević; N Todorović-Raković; M Demajo; V Ivanović; B Nesković; M Markićević; Z Nesković-Konstantinović
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Authors:  Sadia Zafar; Suvi Sorsa; Mikko Siurala; Otto Hemminki; Riikka Havunen; Victor Cervera-Carrascon; João Manuel Santos; Hongjie Wang; Andre Lieber; Tanja De Gruijl; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2018-08-15       Impact factor: 8.110

Review 4.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.

Authors:  R I Nicholson; J M Gee
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

5.  TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.

Authors:  Chenfeng Chen; Kong-Nan Zhao; Paul P Masci; Sunil R Lakhani; Annika Antonsson; Peter T Simpson; Luis Vitetta
Journal:  BMC Cancer       Date:  2015-12-24       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.